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AbsTrACT
The use of genomic information to better understand 
and prevent common complex diseases has been an 
ongoing goal of genetic research. Over the past few 
years, research in this area has proliferated with several 
proposed methods of generating polygenic scores. This 
has been driven by the availability of larger data sets, 
primarily from genome- wide association studies and 
concomitant developments in statistical methodologies. 
Here we provide an overview of the methodological 
aspects of polygenic model construction. in addition, 
we consider the state of the field and implications 
for potential applications of polygenic scores for risk 
estimation within healthcare.
InTroduCTIon
There has been considerable interest in eluci-
dating the contribution of genetic factors to the 
development of common diseases and using this 
information for better prediction of disease risk. 
The common disease common variant hypoth-
esis predicts that variants that are common in the 
population play a role in disease susceptibility.1 
Genome- wide association studies (GWAS) using 
single nucleotide polymorphism (SNP) arrays were 
developed as a mechanism by which to investigate 
these genetic factors and it was hoped this would 
lead to identification of variants associated with 
disease risk and subsequent development of predic-
tive tests. Variants identified as associated with 
particular traits by these studies, for the large part, 
are SNPs that individually have a minor effect on 
disease risk and hence, by themselves, cannot be 
reliably used in disease prediction. Looking at the 
aggregate impact of these SNPs in the form of a 
polygenic score (PGS) appeared to be one possible 
means of using this information to predict disease.2 
It is thought this will be of benefit as our genetic 
make- up is largely stable from birth and dictates a 
‘baseline risk’ on which external influences act and 
modulate. Therefore, PGS are a potential mecha-
nism to act as a risk predictor by capturing informa-
tion on this genetic liability.
The use of PGS as a predictive biomarker is being 
explored in a number of different disease areas, 
including cancer,3 4 psychiatric disorders,5–7 meta-
bolic disorders (diabetes,8 obesity9) and coronary 
artery disease (CAD).10 The proposed applications 
range from aiding disease diagnosis, informing 
selection of therapeutic interventions, improve-
ment of risk prediction, informing disease screening 
and, on a personal level, informing life planning. 
Therefore, genetic risk information in the form of 
a PGS is considered to have potential in informing 
both clinical and individual- level decision- making.
Recent advances in statistical techniques, 
improved computational power and the availability 
of large data sets have led to rapid developments in 
this area over the past few years. This has resulted 
in a variety of approaches to construction of models 
for score calculation and the investigation of these 
scores for prediction of common diseases.11 Several 
review articles aimed at researchers with a working 
knowledge of this field have been produced.6 11–17 
In this article, we provide an overview of the key 
aspects of PGS construction to assist clinicians and 
researchers in other areas of academia to gain an 
understanding of the processes involved in score 
construction. We also consider the implications of 
evolving methodologies for the development of 
applications of PGS in healthcare.
EvoluTIon In polygEnIC modEl 
ConsTruCTIon mEThodologIEs
Terminology with respect to PGS has evolved over 
time, reflecting evolving approaches and method-
ology. Other terms include PGS, polygenic risk 
score, polygenic load, genotype score, genetic 
burden, polygenic hazard score, genetic risk score 
(GRS), metaGRS and allelic risk score. Throughout 
this article we use the terms polygenic models to 
refer to the method used to calculate an output in 
the form of a PGS. Different polygenic models can 
be used to calculate a PGS and analysis of these 
scores can be used to examine associations with 
particular markers or to predict an individuals risk 
of diseases.12
Usual practice in calculating PGS is as a weighted 
sum of a number of risk alleles carried by an indi-
vidual, where the risk alleles and their weights 
are defined by SNPs and their measured effects 
(figure 1).11 Polygenic models have been constructed 
using a few, hundreds or thousands of SNPs, and 
more recently SNPs across the whole genome. 
Consequently, determining which SNPs to include 
and the disease- associated weighting to assign to 
SNPs are important aspects of model construction 
(figure 2).18 These aspects are influenced by avail-
able genotype data and effect size estimates as well 
as the methodology employed in turning this infor-
mation into model parameters (ie, weighted SNPs).
Changes in data availability over time have had 
an impact on the approach taken in SNP selection 
and weighting. Early studies to identify variants 
associated with common diseases took the form of 
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Figure 1 Polygenic score calculation. This calculation aggregates the SNPs and their weights selected for a polygenic score. Common diseases are thought 
to be influenced by many genetic variants with small individual effect sizes, such that meaningful risk prediction necessitates examining the aggregated 
impact of these multiple variants including their weightings. PGS, polygenic score.
Figure 2 Construction of a polygenic score. in the process of developing 
a polygenic score, numerous models are tested and then compared. The 
model that performs best (as determined by one or more measures) is 
then selected for validation in the external data set. GwAS, genome- wide 
association studies.
candidate gene studies. The small size of candidate gene studies, 
the limitation of technologies available for genotyping and strin-
gent significance thresholds meant that these studies investi-
gated fewer variants and those that were identified with disease 
associations had relatively large effect sizes.19 Taken together, 
this meant that a relatively small number of variants were avail-
able for consideration for inclusion in a polygenic model.20 21 
Furthermore, weighting parameters for these few variants were 
often simplistic, such as counts of the number of risk alleles 
carried, ignoring their individual effect sizes.16
The advent of GWAS enabled assessment of SNPs across the 
genome, leading to the identification of a larger number of 
disease- associated variants and therefore more variants suitable 
for inclusion in a polygenic model. In addition, the increasing 
number of individuals in the association studies meant that the 
power of these studies increased, allowing for more precise 
estimates of effect sizes.19 Furthermore, some theorised that 
lowering stringent significance thresholds set for SNP–trait asso-
ciations could also identify SNPs that might play a part in disease 
risk.11 16 This resulted in more options with respect to polygenic 
model parameters of SNPs to include and weights to assign to 
them. However, the inclusion of more SNPs and direct appli-
cation of GWAS effect sizes as a weighting parameter does not 
always equate to better predictive performance.4 16 This is because 
GWAS do not provide perfect information with respect to the 
causal SNP, the effect sizes or the number of SNPs that contribute 
to the trait. Therefore, different methods have been developed 
to address these issues and optimise predictive performance of 
the score. Current common practice is to construct models with 
different iterations of SNPs and weighting, with assessment of 
the performance of each to identify the optimum configuration 
of SNPs and their weights (figure 2).
mEThods usEd In snp sElECTIon And wEIghTIng 
AssIgnmEnT
Some methods of model development will initially involve selec-
tion of SNPs followed by optimisation of weighting, whereas 
others may involve optimisation of weightings for all SNPs that 
have been genotyped using their overall GWAS effect sizes, the 
linkage disequilibrium (LD) and an estimate of the proportion of 
SNPs that are expected to contribute to the risk.22
LD is the phenomenon where some SNPs are coinherited 
more frequently with other SNPs due to their close proximity 
on the genome. Segments with strong LD between SNPs are 
referred to as haplotype blocks. This phenomenon means that 
GWAS often identify multiple SNPs in the same haplotype block 
associated with disease and the true causal SNP is not known. As 
models have started to assess more SNPs, careful consideration is 
required to take into account possible correlation between SNPs 
as a result of this phenomenon. Correlation between SNPs can 
lead to double counting of SNPs and association redundancy, 
where multiple SNPs in a region of LD are identified as being 
associated with the outcome. This can lead to reduction in the 
predictive performance of the model. Therefore, processes for 
filtering SNPs and using one SNP (tag SNP) to act as a marker 
in an area of high LD, through LD thinning, were developed. 
Through these processes SNPs correlated with other SNPs in 
a block are removed, by either pruning or clumping. Pruning 
ignores p value thresholds and ‘eliminates’ SNPs by a process 
of iterative comparison between a pair of SNPs to assess if they 
are correlated, and subsequently could remove SNPs that are 
deemed to have evidence of association. Clumping (also known 
as informed pruning) is guided by GWAS p values and chooses 
the most significant SNP, therefore keeping the most significant 
SNP within a block.23 This is all done with the aim of pinpointing 
relatively small areas of the genome that contribute to risk of 
the trait. Different significance thresholds may be used to select 
SNPs from this subgroup for inclusion in models.
Poor performance of a model can result from imperfect tagging 
with the underlying causal SNP.16 This is because the causal SNP 
that is associated with disease might not be in LD with the tag 
SNP that is in the model but is in LD with another SNP which 
is not in the model. This particularly occurs where the LD and 
variant frequency differs between population groups.24 An alter-
nate approach to filter SNPs is stepwise regression where SNPs 
are selected based on how much the SNPs improve the model’s 
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performance. This is a statistical approach and does not consider 
the impact of LD or effect size.
As described above, early studies used simple weighting 
approaches or directly applied effect sizes from GWAS as 
weighting parameters for SNPs. However, application of effect 
sizes as a weighting parameter directly from a GWAS may not 
be optimal, due to differences in the population that the GWAS 
was conducted in and the target population. Also as described 
above, LD and the fact that not all SNPs may contribute to 
the trait mean that these effect sizes from GWAS are imperfect 
estimates. Therefore, methods have been developed that adjust 
effect size estimates from GWAS using statistical techniques 
which make assumptions about factors such as the number 
of causal SNPs, level of LD between SNPs or knowledge of 
their potential function to better reflect their impact on a trait. 
Numerous statistical methodologies have been developed to 
improve weighting with a view to enhancing the discrimina-
tive power of a PGS.25 26 Examples of some methodological 
approaches are LDpred,22 winner’s curse correction,23 empir-
ical Bayes estimation,27 shrinkage regression (Lasso),28 linear 
mixed models,29 with more being developed or tested. An addi-
tional improvement on the methods is to embed non- genetic 
information (eg, age- specific ORs).6 Determination of which 
methodology or hybrid of methodologies is most appropriate 
for various settings and conditions is continuously being 
explored and is evolving with new statistical approaches devel-
oping at a rapid pace.
In summary, model development has evolved in an attempt to 
gain the most from available GWAS data and address some of 
the issues that arise due to working with data sets which cannot 
be directly translated into parameters for prediction models. 
The different approaches taken in SNP selection and weighting, 
and the impact on the predictive performance of a model are 
important to consider when assessing different models. This 
is because different approaches to PGS modelling can achieve 
the same or a similar level of prediction. From a health system 
implementation perspective, particular approaches may be 
preferred following practical considerations and trade- offs 
between obtaining genotype data, processes for score construc-
tion and model performance. In addition, the degree to which 
these parameters need to be optimised will also be impacted by 
the input data and validation data set, and the quality control 
procedures that need to be applied to these data sets.12
sourCEs oF InpuT dATA For sCorE ConsTruCTIon
Key to the development of a polygenic model is the availability of 
data sets that can provide input parameters for model construc-
tion. Genotype data used in model construction can either be 
available as raw GWAS data or provided as GWAS summary 
statistics. Data in the raw format are individual- level data from 
a SNP array and may not have undergone basic quality control 
such as assessment of missingness, sex discrepancy checks, devi-
ation from Hardy- Weinberg equilibrium, heterozygosity rate, 
relatedness or assessment for outliers.30 31 Availability of raw 
GWAS data allows for different polygenic models to be devel-
oped because of the richness of the data, however computational 
issues arise because of the size of the data sets. Data based on 
genome sequencing, as opposed to SNP arrays, could also be 
used in model construction. There have been limited studies of 
PGS developed from this form of data due to limitations in data 
availability, which is mainly due to cost restraints.15 32 Individual- 
level genomic data are also often not available to researchers due 
to privacy concerns.
Due to these issues, the focus of polygenic model develop-
ment has therefore been on using well- powered GWAS summary 
statistics.33 These are available from open access repositories and 
contain summary information such as the allele positions, ORs, 
CIs and allele frequency, without containing confidential infor-
mation on individuals. These data sets have usually been through 
the basic quality control measures mentioned above. There are, 
however, no standards for publicly available files, meaning some 
further processing steps may be required, in particular when 
various data sets are combined for a meta- analysis. Quality 
control on summary statistics is only possible if information 
such as missing genotype rate, minor allele frequency, Hardy- 
Weinberg equilibrium failures and non- Mendelian transmission 
rates is provided.12
Processing of GWAS data may include additional quality 
control steps, imputation and filtering of the SNP informa-
tion, which can be done at the level of genotype or summary 
statistics data. SNP arrays used in GWAS only have common 
SNPs represented on them as they rely on LD between SNPs to 
cover the entire genome. As described above, one tag SNP on 
the array can represent many other SNPs. Imputation of SNPs 
is common in GWAS and describes the process of predicting 
genotypes that have not been directly genotyped but are statisti-
cally inferred (imputed) based on haplotype blocks from a refer-
ence sequence.33–35 Often association tests between the imputed 
SNPs and trait are repeated. As genotype imputation requires 
individual- level data, researchers have proposed summary statis-
tics imputation as a mechanism to infer the association between 
untyped SNPs and a trait. The performance of imputation has 
been evaluated and shown that, with certain limitations, summary 
statistics imputation is an efficient and cost- effective method-
ology to identify loci associated with traits when compared with 
imputation done on genotypes.36
An alternative source of input data for the selection of SNPs 
and their weightings is through literature or in existing data-
bases, where already known trait- associated SNPs and their 
effect sizes are used as the input parameters in model develop-
ment. A number of studies have taken this approach37 38 and it is 
possible to use multiple sources when developing various poly-
genic models and establishing the preferred parameters to use.
Currently, there does not appear to be one methodology that 
works across all contexts and traits, each trait will need to be 
assessed to determine which method is the most suitable for 
the trait being evaluated. For example, four different polygenic 
model construction strategies were explored for three skin 
cancer subtypes4 by using data on SNPs and their effect sizes from 
different sources, such as the latest GWAS meta- analysis results, 
the National Human Genome Research Institute (NHGRI) EBI 
GWAS catalogue, UK Biobank GWAS summary statistics with 
different thresholds and GWAS summary statistics with LDpred. 
In this setting for basal cell carcinoma and melanoma, the meta- 
analysis and catalogue- derived models were found to perform 
similarly but that the latter was ultimately used as it included 
more SNPs. For squamous cell carcinoma the meta- analysis- 
derived model performed better than the catalogue- derived 
model. This demonstrates how each disease subtype, model 
construction strategy and data set can have their own limitations 
and advantages.
Knowledge of the sources of input data and its subsequent 
use in model development is important in understanding the 
limitations of available models. Models that are developed using 
data sets that reflect the population in which prediction is to be 
carried out will perform better. For example, data collected from 
a symptomatic or high- risk population may not be suitable as an 
 o
n
 M
ay 15, 2020 at BVA. Protected by copyright.
http://jmg.bmj.com/
J M
ed G
enet: first published as 10.1136/jmedgenet-2019-106763 on 6 May 2020. Downloaded from 
4 Babb de Villiers C, et al. J Med Genet 2020;0:1–8. doi:10.1136/jmedgenet-2019-106763
 
Figure 3 example distribution of polygenic scores across a population. 
Thresholds can be set to stratify risk as low (some), average (most) and 
high (some).
input data set for the development of a polygenic model that will 
be used for disease prediction in the general population. Large 
GWAS studies were previously focused on high- risk individuals, 
such as patients with breast cancer with a strong family history 
or known pathogenic variants in BRCA1 or BRCA2. These 
studies would not be suitable for the development of PGS for 
use in the general population but can inform risk assessment in 
high- risk individuals. The source of the data for SNP selection 
and weighting also has implications for downstream uses and 
validation. For example, variant frequency and LD patterns can 
vary between populations and this can translate to poor perfor-
mance of the polygenic model if the external validation popula-
tion is different from that of the input data set.39–41 Furthermore, 
the power and validity of polygenic analyses are influenced by 
the input data sources.12 42
From A modEl To A sCorE
PGS can be calculated using one of the methodologies discussed 
above. The resulting PGS units of measurement depend on 
which measurement is used for the weighting.12 For example, 
the weightings may have been calculated based on logOR for 
discrete traits or linear regression coefficient (β/beta) in contin-
uous traits from univariate regression tests carried out in the 
GWAS. The resulting scores are then usually transformed to a 
standard normal distribution to give scores ranging from −1 to 
1, or 0 to 100 for ease of interpretation. This enables further 
examination of the association between the score and a trait and 
the predictive ability of different scores generated by different 
models. Similar to other biomarker analyses, this involves using 
the PGS as a predictor of a trait with other covariates (eg, age, 
smoking, and so on) added, if appropriate, in a target sample. 
Examination of differences in the distribution of scores in cases 
and controls, or by examining differences in traits between 
different strata of PGS can enable assessment of predictive ability 
(figure 3). Common practice is for individual- level PGS values to 
be used to stratify populations into distinct groups of risk based 
on percentile cut- off or threshold values (eg, the top 1%).
modEl vAlIdATIon
Polygenic model development is reliant on further data sets for 
model testing and validation and the composition of these data 
sets is important in ensuring that the models are appropriate for 
a particular purpose. The development of a model to calculate 
a PGS involves refinement of the previously discussed input 
parameters, and selection of the ‘best’ of several models based on 
performance (figure 2). Therefore, a testing/training data set is 
often required to assess the model’s ability to accurately predict 
the trait of interest. This is often a data set that is independent 
of the base/input/discovery data set. It may comprise a subset 
of the discovery data set that is only used for testing and was 
not included in the initial development of the model but should 
ideally be a separate independent data set.
Genotype and phenotype data are needed in these data sets. 
Polygenic models are used to calculate PGS for individuals in 
the training data set and regression analysis is performed with 
the PGS as a predictor of a trait; other covariates may also be 
included, if appropriate. This testing phase can be considered a 
process for identifying models with better overall performance 
and/or informing refinements needed. Hence, this phase often 
involves comparison of different models that are developed 
using the same input data set to identify those models that have 
optimal performance.
The primary purpose is to determine which model best discrim-
inates between cases and controls. The area under the curve 
(AUC) or the C- statistic is the most commonly used measure in 
assessing discriminative ability. It has been criticised as being an 
insensitive measure that is not able to fully capture all aspects 
of predictive ability. For instance, in some instances, AUC can 
remain unchanged between models but the individuals within are 
categorised into a different risk group.43 Alternative metrics that 
have been used to evaluate model performance include increase 
in risk difference, integrated discrimination improvement, 
R2 (estimate of variance explained by the PGS after covariate 
adjustment), net classification index and the relative risk (highest 
percentile vs lowest percentile). A clear understanding on how to 
interpret the performance within various settings is important in 
determining which model is most suitable.44
As per normal practice when developing any prediction 
model, polygenic models with the optimal performance in a 
testing/training data set should be further validated in external 
data sets. External data sets are critical in validation of models 
and assessment of generalisability, hence must also conform to 
the desired situations in which a model is to be used. The goal 
is to find a model with suitable parameters of predictive perfor-
mance in data sets outside of those in which it was developed. 
Ideally, external validation requires replication in independent 
data sets. Few existing polygenic models have been validated to 
this extent, the focus being rather on the development of new 
models rather than evaluation of existing ones. One example 
where replication has been carried out is in the field of CAD, 
where the GPSCAD
45 and metaGRSCAD
10 polygenic models (both 
developed using UK Biobank data) were evaluated in a Finnish 
population cohort.46 Predictive ability was found to be lower 
in the Finnish population. This is likely to be due to the differ-
ences in genetic structure of this population and the population 
of the data set used for polygenic model development. Research 
is ongoing to evaluate polygenic models in other populations 
and strategies are being developed to ensure the same perfor-
mance when used more widely, possibly through reweighting 
and adjustment of the scores.47
movIng TowArds ClInICAl ApplICATIons
PGS are thought to be useful information that could improve 
risk estimation and provide an avenue for disease prevention 
and deciding treatment strategies. There are indications from a 
number of fields that genetic information in the form of PGS 
can act as independent biomarkers and aid stratification.11 16 48 
However, the clinical benefits of stratification using a PGS and 
the implications for clinical practice are only just beginning to 
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be examined. The use of PGS as part of existing risk prediction 
tools or as a stand- alone predictor has been suggested. This latter 
option may be true for diseases where knowledge or predictive 
ability with other risk factors is limited, such as in prostate 
cancer.49 In either case, polygenic models need to be individu-
ally examined to determine suitability and applicability for the 
specific clinical question.50 Despite some commercial companies 
developing PGS,51 52 currently PGS are not an established part of 
clinical practice.
Integration into clinical practice requires evaluation of a PGS- 
based test. An important concept to consider in this regard is the 
distinction between an assay and a test. This has been previously 
discussed with respect to genetic test evaluation.53 54 It is worth 
examining this concept as applied to PGS, as their evaluation 
is reliant on a clear understanding of the test to be offered. As 
outlined by Zimmern and Kroese,54 the method used to analyse 
a substance in a sample is considered the assay, whereas a test 
is the use of an assay within a specific context. With respect to 
PGS, the process of developing a model to derive a score can be 
considered the assay, while the use of this model for a particular 
disease, population and purpose can be considered the test. This 
distinction is important when assessing if studies are reporting 
on assay performance as opposed to test performance. It is our 
view that, with respect to polygenic models, progress has been 
made with respect to assay development, but PGS- based tests 
are yet to be developed and evaluated. This can enable a clearer 
understanding of their potential clinical utility and issues that 
may arise for clinical implementation.11 18 55 It is clear that this is 
still an evolving field, and going forward different models may 
be required for different traits due to their underlying genetic 
architecture,26 different clinical contexts and needs.
Clinical contexts where risk stratification is already estab-
lished practice are most likely where implementation of PGS 
will occur first. Risk prediction models based on non- genetic 
factors have been developed for many conditions and are used 
in clinical care, for example, in cardiovascular disease over 100 
such models exist.56 In such contexts, how a PGS and its ability 
to predict risk compared with, or improves on, these existing 
models is being investigated.3 44 57–61 The extent to which PGS 
improves prediction, as well as the cost implications of including 
this, is likely to impact on implementation.
Integration of PGS into clinical practice, for any applica-
tion, requires robust and validated mechanisms to generate 
these scores. Therefore, given the numerous models available, 
an assessment of their suitability as part of a test is required. 
Parameters or guidelines with respect to aspects of model perfor-
mance and metrics that could assist in selecting the model to 
take forward as a PGS- based test are limited and need to be 
addressed. Currently, there are different mechanisms to generate 
PGS and have arisen in response to the challenges in aggregating 
large- scale genomic data for prediction. For example, a review 
reported 29 PGS models for breast cancer from 22 publica-
tions.62 Due to there being a number of different methodologies 
to generate a score, numerous models may exist for the same 
condition and each of the resulting models could perform differ-
ently. Models may perform differently because the population, 
measured outcome or context of the development data sets used 
to generate the models is diverse, for example, a score for risk of 
breast cancer versus a breast cancer subtype.44 63 This diversity, 
alongside the lack of established best practice and standardised 
reporting in publications, makes comparison and evaluation 
of polygenic models for use in clinical settings challenging. It 
is clear that moving the field forward is reliant on transparent 
reporting and evaluation. Recommendations for best practices 
on the reporting of polygenic models in literature have been 
proposed14 64 as well as a database,65 66 which could allow for 
such comparisons. Statements and guidelines for risk predic-
tion model development, such as the Genetic Risk Prediction 
Studies and Transparent Reporting of a Multivariable Prediction 
Model for Individual Prognosis or Diagnosis (TRIPOD), already 
exist, but are not consistently used. TRIPOD explicitly covers 
the development and validation of prediction models for both 
diagnosis and prognosis, for all medical domains.
One clear issue is generalisability and drop in performance of 
polygenic models once they are applied in a population group 
different from the one in which they were developed.22 46 67–70 
This is an ongoing challenge in genomics as most GWAS, from 
which most PGS are being developed, have been conducted in 
European- Caucasian populations.71 Efforts to improve represen-
tation are underway72 and there are attempts to reweight/adjust 
scores when applied to different population groups which are 
showing some potential but need further research.47 Others have 
demonstrated that models developed in more diverse population 
groups have improved performance when applied to external 
data sets in different populations.24 73 It is important to consider 
this issue when moving towards clinical applications as it may 
pose an ethical challenge if the PGS is not generalisable.
A greater understanding of different complex traits and the 
impact of pleiotropy is only beginning to be investigated.74 There 
is growing appreciation of the role of pleiotropy as multiple vari-
ants have been identified to be associated with multiple traits and 
exert diverse effects, providing insight into overlapping mecha-
nisms.75 76 This, together with the impact of population stratifi-
cation, genetic relatedness, ascertainment and other sources of 
heterogeneity leading to spurious signals and reduced power in 
genetic association studies, all impacting on the predictive ability 
of PGS in different populations and for different diseases.
While many publications report on model development 
and evaluation, often there is a lack of clarity on intended 
purpose,50 77 leading to uncertainties as to the clinical pathways 
in which implementation is envisaged. A clear description of 
intended use within clinical pathways is a central component 
in evaluating the use of an application with any form of PGS 
and in considering practical implications, such as mechanisms 
of obtaining the score, incorporation into health records, inter-
pretation of scores, relevant cut- offs for intervention initiation, 
mechanisms for feedback of results and costs, among other 
issues. These parameters will also be impacted by the polygenic 
model that is taken forward for implementation. Meaning that 
there are still some important questions that need to be addressed 
to determine how and where PGS could work within current 
healthcare systems, particularly at a population level.78
It is widely accepted that genotyping using arrays is a lower 
cost endeavour in comparison to genome sequencing, making 
the incorporation of PGS into routine healthcare an attrac-
tive proposition. However, we were unable to find any studies 
reporting on the use or associated costs of such technology for 
population screening. Studies are beginning to examine use case 
scenarios and model cost- effectiveness, but this has only been 
in very few, specific investigations.79 80 Costs will also be influ-
enced by the testing technology and by the downstream conse-
quences of testing, which is likely to differ depending on specific 
applications that are developed and the pathways in which such 
tests are incorporated. This is particularly the case in screening 
or primary care settings, where such testing is currently not an 
established part of care pathways and may require additional 
resources, not least as a result of the volume of testing that could 
be expected. Moving forward, the clinical role of PGS needs to 
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be developed further, including defining the clinical applications 
as well as supporting evidence, for example, on the effect of 
clinical outcomes, the feasibility for use in routine practice and 
cost- effectiveness.
ConClusIon
There is a large amount of diversity in the PGS field with respect 
to model development approaches, and this continues to evolve. 
There is rapid progress which is being driven by the availability 
of larger data sets, primarily from GWAS and concomitant 
developments in statistical methodologies. As understanding 
and knowledge develops, the usefulness and appropriateness of 
polygenic models for different diseases and contexts are being 
explored. Nevertheless, this is still an emerging field, with a vari-
able evidence base demonstrating some potential. The validity 
of PGS needs to be clearly demonstrated, and their applications 
evaluated prior to clinical implementation.
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